Yen Y. Tan
A5040334417- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Ovarian cancer diagnosis and treatment
- Breast Cancer Treatment Studies
- Genetic Associations and Epidemiology
- HER2/EGFR in Cancer Research
- DNA Repair Mechanisms
- CRISPR and Genetic Engineering
- Nutrition, Genetics, and Disease
- PARP inhibition in cancer therapy
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Cancer Risks and Factors
- Global Cancer Incidence and Screening
- Male Breast Health Studies
- Genomic variations and chromosomal abnormalities
- Gene expression and cancer classification
- Prostate Cancer Treatment and Research
- Cancer survivorship and care
- Cancer-related molecular mechanisms research
- Cancer and Skin Lesions
- Cancer Cells and Metastasis
- Salivary Gland Tumors Diagnosis and Treatment
- Bioinformatics and Genomic Networks
Medical University of Vienna
2016-2025
Comprehensive Cancer Center Vienna
2016-2025
Vienna General Hospital
2023
Carrier (United States)
2021
Cohort (United Kingdom)
2021
Ng Teng Fong General Hospital
2019
QIMR Berghofer Medical Research Institute
2012-2018
Inserm
2018
Institut Curie
2018
Centro de Investigación Biomédica en Red
2018
<h3>Importance</h3> The clinical management of<i>BRCA1</i>and<i>BRCA2</i>mutation carriers requires accurate, prospective cancer risk estimates. <h3>Objectives</h3> To estimate age-specific risks of breast, ovarian, and contralateral breast for mutation to evaluate modification by family history location. <h3>Design, Setting, Participants</h3> Prospective cohort study 6036<i>BRCA1</i>and 3820<i>BRCA2</i>female (5046 unaffected 4810 with or ovarian both at baseline) recruited in 1997-2011...
Clinicopathologic data from a population-based endometrial cancer cohort, unselected for age or family history, were analyzed to determine the optimal scheme identification of patients with germline mismatch repair (MMR) gene mutations.Endometrial cancers 702 recruited into Australian National Endometrial Cancer Study (ANECS) tested MMR protein expression using immunohistochemistry (IHC) and MLH1 promoter methylation in MLH1-deficient cases. mutation testing was performed on DNA MMR-protein...
To provide precise age-specific risk estimates of cancers other than female breast and ovarian associated with pathogenic variants (PVs) in
We aimed to establish whether morphologic parameters were prognostically important in a large series of breast phyllodes tumors Asian women. Of 335 diagnosed at the Department Pathology, Singapore General Hospital, Singapore, between January 1992 and December 2002, 250 (74.6%) benign, 54 (16.1%) borderline, 31 (9.3%) malignant, based on histologic review archival slides. women, 43 (12.8%) experienced recurrences during follow-up period. Recurrent disease was correlated with grade or...
We aimed to establish whether morphologic parameters were prognostically important in a large series of breast phyllodes tumors Asian women. Of 335 diagnosed at the Department Pathology, Singapore General Hospital, Singapore, between January 1992 and December 2002, 250 (74.6%) benign, 54 (16.1%) borderline, 31 (9.3%) malignant, based on histologic review archival slides. women, 43 (12.8%) experienced recurrences during follow-up period. Recurrent disease was correlated with grade or...
Breast cancer is the most common female cancer, affecting approximately one in eight women during their life-time. Besides environmental triggers and hormones, inherited mutations breast 1 (BRCA1) or BRCA2 genes markedly increase risk for development of cancer. Here, using two different mouse models, we show that genetic inactivation key osteoclast differentiation factor RANK mammary epithelium delayed onset, reduced incidence, attenuated progression Brca1;p53 mutation-driven Long-term...
Abstract Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective but may be substantially biased. Prospective studies had limited power, particularly carriers. Further, previous not considered the RRSO in context natural menopause. Methods A multi-centre prospective cohort 2272 1605 was followed mean 5.4 4.9 years, respectively; 426 women developed incident...
The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early detection risk reduction this population.
Ovarian cancer risk in BRCA1 and BRCA2 mutation carriers has been shown to decrease with longer duration of oral contraceptive use. Although the effects using contraceptives general population are well established (approximately 50% reduction ovarian cancer), estimated is much less precise because potential bias small sample sizes. In addition, only a few studies on use have examined associations use, time since last starting age, calendar year start cancer.
Abstract Background For BRCA1 and BRCA2 mutation carriers, the association between oral contraceptive preparation (OCP) use breast cancer (BC) risk is still unclear. Methods Breast camcer associations were estimated from OCP data on 6030 3809 carriers using age-dependent Cox regression, stratified by study birth cohort. Prospective, left-truncated retrospective full-cohort analyses performed. Results was not associated with BC in prospective (hazard ratio [HR] = 1.08, 95% confidence interval...
The risk of developing endometrial cancer (EC) and/or survival following a diagnosis EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and EC.We analyzed data from women who participated in Australian National Endometrial Cancer Study (ANECS) conducted 2005 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic lifestyle information...
Abstract Purpose: To evaluate whether pathologic complete response (pCR) to neoadjuvant trastuzumab is dependent on the level of HER2 amplification. Experimental Design: 114 HER2-overexpressing early breast cancer patients who had received were included in this study. Absolute and chromosome 17 centromere (CEP17) measured by situ hybridization analysis, associations examined between HER2/CEP17 ratio tumor pCR status (commonly defined ypT0 ypN0, ypT0/is ypT0/is). Results: In...
Tobacco smoking and alcohol consumption have been intensively studied in the general population to assess their effects on risk of breast cancer, but very few studies examined these
Background: Breast cancer (BC) patients with germline BRCA1/2 pathogenic variants (PVs) often face unique challenges compared to non-carriers. However, the impact of PVs on treatment patterns, clinical outcomes, and quality life (QoL) remains insufficiently explored. This study aims assess these factors in individuals. Methods: A retrospective analysis was conducted using data from Medical University Vienna Center for Familial Ovarian Cancer between 2011 2021. Among 1285 individuals...
Cowden syndrome (CS) is a rare hereditary disorder characterized by benign overgrowth in various tissues and high risk of breast thyroid cancer. CS closely associated with pathogenic variants (PVs) the phosphatase tensin homolog (PTEN) tumor suppressor gene. PVs PTEN are usually inherited estimates de novo frequencies remain inconclusive. The diagnosis PTEN-associated syndromes remains challenge clinical practice, due to patients showing seemingly unrelated symptoms. We report on management...
Full-term pregnancy (FTP) is associated with a reduced breast cancer (BC) risk over time, but women are at increased BC in the immediate years following an FTP. No large prospective studies, however, have examined whether number and timing of pregnancies for
The distribution of ovarian tumour characteristics differs between germline BRCA1 and BRCA2 pathogenic variant carriers non-carriers. In this study, we assessed the utility as predictors pathogenicity, for application using American College Medical Genetics Association Molecular Pathology (ACMG/AMP) classification system.
Current evidence suggests poor identification and referral of Lynch syndrome patients. This study evaluated the strategies by which patients with endometrial cancer were referred to genetics services. Data from clinic-based enrolled through Australian National Endometrial Cancer population-based research detailed family history information analyzed. The Amsterdam II criteria, revised Bethesda guidelines, criteria adapted for this was assessed using personal/family information. percentages...
This article explores the views of general practitioners and specialists on their referral patients with suspected Lynch syndrome to cancer genetic services. Using a purposive maximum variation sampling strategy, we conducted semi-structured interviews face-to-face 28 in public or private hospitals specialist clinics between March August 2011. General were recruited major metropolitan area Australia. Interview transcripts reviewed by two independent researchers, thematic analysis was...
Loss of expression cadherin-11 protein is correlated with a loss epithelial phenotype and gain in tumor cell proliferation invasion. It has been hypothesized that may be molecular marker for more aggressive subtype breast cancer. The present study examined the mesenchymal gene/protein cadherin‑11 malignant, benign healthy cancer samples. A paraffin‑embedded tissue microarray both malignant benign/healthy was used. Clinicopathological parameters, including age, grading, size, hormone...
Abstract We investigated the prevalence of germline BRCA mutations in a population‐based cohort Austrian women diagnosed with ovarian cancer and its association family history cancer. prospectively collected pedigrees 443 patients who had been tested for presence or 2 correlated familial breast burden disease onset. The probability carrying g mutation without is 14% (95% CI 9%‐22%), as opposed to 45% 31%‐59%) at least one member cancer, 47% 40%‐54%) if other relatives have developed If both...
Background: BRCA 1/2 mutation status has become one of the most important parameters for treatment decision in patients with epithelial ovarian cancer (EOC). The aim this study was to compare tumor DNA blood sequencing evaluate reliability testing results. Methods: Patients who were treated EOC between 2003 and 2019 at Medical University Vienna underwent both germline (gBRCA) (tBRCA) mutations identified. We calculated concordance rate further analyzed discordant cases. Results: Out 140 EOC,...